Small Cell Lung Cancer (SCLC): An Insight

What Is Small Cell Lung Cancer?

Small Cell Lung Cancer (SCLC) is one of the most malignant forms of lung cancer, making up about 15% of lung cancer cases worldwide. The name “oat cell carcinoma” comes from the fact that these cancer cells are small, oval-shaped, and flat, resembling oats when viewed under a microscope.

SCLC primarily develops within the central bronchi. It is a fast-growing cancer, which replicates at an average rate of doubling every 25 to 30 days. It also metastasizes early in distant organs.

Types of Small Cell Lung Cancer

SCLC is classified into two histological subtypes:

• Small Cell Carcinoma (Oat Cell Carcinoma): This is the most common form, accounting for approximately 95 to 98% of all SCLC (small-cell lung cancer) cases. The cells are small, round, or oval with dark nuclei and very little cytoplasm. They originate from neuroendocrine precursor cells in the airway lining and grow and spread extremely rapidly.

• Combined Small Cell Carcinoma: This is a rarer subtype in which SCLC cells are mixed with components of non-small cell lung cancer, such as adenocarcinoma or squamous cell carcinoma. It represents about 2 to 5% of all SCLC cases. It may respond differently to treatment than pure SCLC.

Causes and Risk Factors

1. Causes

• Smoking: The most common reason behind SCLC is cigarette smoking, which contributes to nearly 98% of all the cases, according to the NCI. The higher the pack-years of smoking, the greater the risk becomes. Very few cases of SCLC are found in people who have never smoked in their entire life, less than 2%.

• There are several carcinogenic substances found in cigarette smoke, such as polycyclic aromatic hydrocarbons (PAHs), N-nitrosamines, benzene, arsenic, and chromium. It induces mutations in DNA, which leads to cell proliferation.

2. Other Risk Factors

• Secondhand Smoke: Regular exposure to others' cigarette smoke increases lung cancer risk by approximately 20 to 30%.

• Radon Gas: A colorless, odorless, naturally occurring radioactive gas that can seep into homes. It is the second leading cause of lung cancer in the US (US Environmental Protection Agency).

• Occupational Carcinogens: It includes asbestos, arsenic, nickel, chromium, and diesel exhaust.

• Prior Chest Radiation: People who received chest radiation for other cancers face a higher risk.

• HIV Infection: Linked to a modestly increased risk of lung cancer, including SCLC.

• Family History: Having a first-degree relative with lung cancer roughly doubles personal risk.

Symptoms of Small Cell Lung Cancer

SCLC that has not spread beyond the chest rarely causes symptoms in its earliest stages. When symptoms do appear, they typically reflect either local tumor effects (on the airway, blood vessels, or nerves) or the effects of distant metastasis.

1. Common Symptoms

• Severe cough that becomes worse over time.

• Hemoptysis (coughing up blood).

• Breathing difficulties.

• Tightness or soreness in the chest.

• Hoarseness or voice changes.

• Facial and neck swelling (from superior vena cava syndrome - see below).

• Swollen neck veins.

• Unexplained weight loss.

• Loss of appetite.

• Persistent fatigue.

2. Symptoms from Metastasis

When SCLC has spread beyond the chest, additional symptoms may include:

• Bone pain (back, hips, ribs) from bone metastasis.

• Headaches, dizziness, confusion, or seizures from brain metastasis

• Yellowing of the skin and eyes (jaundice) from liver metastasis

• Weakness in the legs or arms, from spinal cord compression

3. Paraneoplastic Syndromes (Unique to SCLC)

Small-cell lung cancer is most likely to cause paraneoplastic syndromes of the whole body due to hormones or antibodies that the cancer generates, unrelated to its spread. This can occur even prior to diagnosis:

4. SIADH (Syndrome of Inappropriate Antidiuretic Hormone)

SCLC cells produce ADH (antidiuretic hormone), causing the kidneys to retain excess water. This lowers blood sodium levels (hyponatremia) and causes fatigue, confusion, nausea, muscle cramps, and in severe cases, seizures and coma. SIADH occurs in 10 to 15% of SCLC patients.

5. Lambert-Eaton Myasthenic Syndrome (LEMS)

The antibodies produced by the immune system affect calcium channels at the neuromuscular junctions, leading to problems with muscle contraction. The signs associated with LEMS include proximal muscle weakness (thighs and hips) and difficulty climbing stairs. Improvement of strength with repetitive use is another sign.

6. Cushing's Syndrome

These cells synthesize ACTH, which increases cortisol synthesis, leading to increased body weight, especially in the facial and abdominal regions, hypertension, elevated blood glucose levels, easily bruised skin, and muscular atrophy.

7. Superior Vena Cava (SVC) Syndrome

If there is a tumor or swollen lymph node pressing on the superior vena cava, blood will collect in the face and upper limbs. There will be swelling of the face and upper limbs, changes in skin color, headaches, and difficulty breathing.

Stages of Small Cell Lung Cancer

SCLC uses a two-stage classification system originally developed for radiation planning, and now used alongside the TNM staging system:

• Limited Stage SCLC (LS-SCLC): Cancer is confined to one lung and possibly nearby lymph nodes on the same side of the chest, within a single radiation field. Approximately 30% of SCLC patients are diagnosed at this stage. Treatment with chemotherapy plus concurrent chest radiation is standard. Some patients are curable at this stage.

• Extensive Stage SCLC (ES-SCLC): The disease has already spread to other areas, such as the opposite lung, lymph nodes, or distant organs like the brain, liver, bones, and adrenal glands. Around 70% of all small-cell lung cancer cases fall into this category. Chemotherapy, along with immunotherapy, is used for treatment.

Survival Rate by Stage

Stage	5-Year Survival Rate	Median Survival
Limited Stage (LS-SCLC)	~29%	15 to 20 months
Extensive Stage (ES-SCLC)	~3%	8 to 13 months
Overall (all SCLC)	~7%	~7 months

These data represent averages within the general population. Results may vary based on age, performance score, response to primary therapy, and the presence of molecular markers that can guide treatment.

How Is Small Cell Lung Cancer Diagnosed?

The process of diagnosis involves two steps, which are imaging for detecting the tumor and analyzing tissue to know the type of cell involved:

• Chest X-Ray: Typically the first test may show a central mass or mediastinal widening.

• CT Scan of the Chest, Abdomen, and Pelvis: Maps the extent of the tumor and lymph node involvement.

• PET Scan: Detects areas of active metabolic activity throughout the body to identify metastases.

• MRI of the Brain: Mandatory in SCLC (small-cell lung cancer) workup; brain metastases are present in 10 to 15% of patients at diagnosis.

• Bronchoscopy with Biopsy: A camera is passed into the airway; tissue is sampled from the tumor for pathological analysis.

• CT-Guided Needle Biopsy: Used for peripheral masses or lymph node sampling.

• Bone Marrow Biopsy: Occasionally performed to detect bone marrow involvement.

• Blood Tests: Including LDH (lactate dehydrogenase, a marker of tumor burden), sodium (to detect SIADH), and full blood count.

Pathological analysis confirms the diagnosis and distinguishes SCLC from NSCLC and other neuroendocrine tumors such as carcinoid tumors.

Treatment of Small Cell Lung Cancer

1. Limited Stage SCLC

Concurrent Chemoradiation: It is the standard of care for limited-stage disease. Chemotherapy (typically Etoposide + Cisplatin or Carboplatin, given in 4 to 6 cycles) is delivered simultaneously with chest radiation therapy.

• Concurrent (simultaneous) chemoradiation achieves better outcomes than sequential treatment.

• Early initiation of chest radiation (with the first or second cycle of chemotherapy) is recommended.

• Approximately 80 to 90% of patients with limited-stage SCLC respond to initial treatment.

2. Extensive Stage SCLC

Chemotherapy + Immunotherapy: It is the current first-line standard:

• Etoposide + Carboplatin/Cisplatin (4 cycles) combined with either:

  • Atezolizumab (anti-PD-L1): FDA (Food and Drug Administration) approved in 2019 in combination with chemotherapy for ES-SCLC (Extensive-stage small-cell lung cancer). Improved median overall survival by approximately 2 months.

  • Durvalumab (anti-PD-L1): In 2024, the FDA approved the use of Durvalumab alongside chemotherapy for limited-stage SCLC (small cell lung cancer)..

3. Prophylactic Cranial Irradiation or PCI:

Because SCLC spreads to the brain in up to 40 to 50% of patients who achieve a good response to initial treatment, preventive radiation to the brain (PCI) is offered to selected patients. PCI reduces the risk of brain metastases and can improve survival in patients with limited-stage disease. It is given after chemotherapy is complete, when the patient has responded well to treatment.

MRI of the brain is now often used as an alternative to PCI in extensive-stage patients to monitor for brain metastases and treat them early.

4. Second-Line Treatment (Relapsed SCLC)

Most SCLC cases relapse within 6 to 12 months of first-line treatment. Second-line options depend on the time to relapse:

• Sensitive Relapse (more than 90 days after completing first-line): Topotecan (oral or IV) is standard. Response rates of 20 to 25%.

• Refractory Relapse (less than 90 days): Lurbinectedin (received FDA accelerated approval in 2020 for relapsed SCLC) achieves response rates of approximately 35% in platinum-refractory patients.

• Other options include: Irinotecan, Paclitaxel, Gemcitabine, and clinical trials.

5. Surgery

Surgery is rarely used in SCLC. It may be considered in a very small subset of patients with very early-stage disease (Stage I, T1-2N0) confirmed on PET and brain MRI, approximately 5% of all SCLC patients. Even when resected, adjuvant chemotherapy is always given.

How Is SCLC Different from NSCLC?

Feature	SCLC	NSCLC
Proportion of Lung Cancers	~15%	~85%
Growth Rate	Very rapid (doubles every 25 to 30 days)	Slower
Typical Location	Central (near bronchi)	Peripheral or central
Smoking Association	Almost always (98%)	Strong but less absolute
Surgery Role	Rarely appropriate	Mainstay of early-stage treatment
Response to Chemotherapy	Excellent initially	Variable
Paraneoplastic Syndromes	Common (SIADH, LEMS, Cushing's)	Less common
Targetable Mutations	Very rare (no standard targeted therapy)	Common (EGFR, ALK, ROS1, KRAS)

When to See a Doctor?

See a doctor promptly if you smoke or have smoked and experience any of the following:

• A persistent cough lasting more than 8 weeks.

• Coughing up blood, even once.

• Unexplained shortness of breath or wheezing.

• Facial or neck swelling.

• Unexplained weight loss of more than 11 lbs (pounds) in a few weeks.

• Muscle weakness in the hips or thighs.

• Confusion, low sodium symptoms, or persistent nausea without a clear cause.

SCLC is rarely caught at a stage where it is fully curable, but the earlier it is found, the more treatment options are available and the better the outcome.

Conclusion

Small-cell lung cancer moves faster than almost any other cancer. By the time symptoms appear, the disease has often already spread. That is why a cough that lingers, unexplained weakness, or facial swelling should never be dismissed in anyone with a smoking history.

If you or a loved one has been diagnosed with SCLC or is experiencing unexplained symptoms, specialist input matters early.

Consult a doctor online at iCliniq - get cancer specialist guidance without the wait.

Key Takeaways

• Small cell lung cancer (SCLC) is the most aggressive form of lung cancer, accounting for approximately 15% of all cases worldwide.

• It is almost exclusively caused by cigarette smoking; fewer than 2% of SCLC cases occur in people who have never smoked.

• SCLC spreads rapidly to the brain, liver, bones, and adrenal glands, often before any symptoms appear.

• The 5-year survival rate for limited-stage SCLC is approximately 29%; for extensive-stage SCLC, it is approximately 3%.

• SCLC is highly sensitive to chemotherapy and radiation therapy, though most cases relapse within months.

• Immunotherapy drugs (Atezolizumab, Durvalumab) have recently improved outcomes in extensive-stage disease.

• Diagnosed with SCLC or concerned about symptoms? Consult a specialist online at iCliniq for expert guidance.